This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coviello, A. D. Articles by Bhasin, S. Search for Related Content PubMed PubMed Citation Articles by Coviello, A. D. Articles by Bhasin, S. Related Collections Male Endocrinology

Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men

Section of Endocrinology, Diabetes, and Nutrition (A.D.C., B.K., K.M.L., T.C., S.B.), Boston University School of Medicine, Boston, Massachusetts 02118; and Charles R. Drew University (A.B.S.), Los Angeles, California 90059

Address all correspondence and requests for reprints to: Andrea D. Coviello, M.D., Department of Medicine, Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, 670 Albany Street, 2nd Floor, Boston, Massachusetts 02118. E-mail: andrea.coviello{at}bmc.org.

Context: Erythrocytosis is a dose-limiting adverse effect of testosterone therapy, especially in older men.

Objective: Our objective was to compare the dose-related changes in hemoglobin and hematocrit in young and older men and determine whether age-related differences in erythropoietic response to testosterone can be explained by changes in erythropoietin and soluble transferrin receptor (sTfR) levels.

Design: We conducted a secondary analysis of data from a testosterone dose-response study in young and older men who received long-acting GnRH agonist monthly plus one of five weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 wk.

Setting: The study took place at a General Clinical Research Center.

Participants: Participants included 60 older men aged 60–75 yr and 61 young men aged 19–35 yr.

Outcome Measures: Outcome measures included hematocrit and hemoglobin and serum erythropoietin and sTfR levels.

Results: Hemoglobin and hematocrit increased significantly in a linear, dose-dependent fashion in both young and older men in response to graded doses of testosterone (P < 0.0001). The increases in hemoglobin and hematocrit were significantly greater in older than young men. There was no significant difference in percent change from baseline in erythropoietin or sTfR levels across groups in either young or older men. Changes in erythropoietin or sTfR levels were not significantly correlated with changes in total or free testosterone levels.

Conclusions: Testosterone has a dose-dependent stimulatory effect on erythropoiesis in men that is more pronounced in older men. The testosterone-induced rise in hemoglobin and hematocrit and age-related differences in response to testosterone therapy may be mediated by factors other than erythropoietin and sTfR.

This article has been cited by other articles:

				J W Jacobeit, L J Gooren, and H M Schulte Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals Eur. J. Endocrinol., November 1, 2009; 161(5): 795 - 798. [Abstract] [Full Text] [PDF]

				G. Caminiti, M. Volterrani, F. Iellamo, G. Marazzi, R. Massaro, M. Miceli, C. Mammi, M. Piepoli, M. Fini, and G. M.C. Rosano Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol., September 1, 2009; 54(10): 919 - 927. [Abstract] [Full Text] [PDF]

				G. F. Gonzales, M. Gasco, V. Tapia, and C. Gonzales-Castaneda High serum testosterone levels are associated with excessive erythrocytosis of chronic mountain sickness in men Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1319 - E1325. [Abstract] [Full Text] [PDF]